The Molecular Diagnosis and Therapy industry trends over the past 18 months highlight accelerated innovation driven by partnerships and technological advancements. Notably, Thermo Fisher Scientific and Danaher Corporation expanded their portfolios through strategic acquisitions in next-generation sequencing (NGS) and companion diagnostic development. Collaborations, such as Qiagen and Guardant Health, underscored the growing emphasis on liquid biopsy solutions for early cancer detection. Regulatory momentum, including the FDA’s updated framework for digital companion diagnostics, has streamlined approvals for AI-integrated platforms like F. Hoffmann-La Roche’s AI-powered molecular analysis tool. Consumer demand for home-based molecular testing, exemplified by Color Genomics’ affordable hereditary cancer screening kit, reflects a shift toward decentralized diagnostics. Enterprise investments in CRISPR-based technologies, such as Editas Medicine’s partnership with Moderna, signal a pivot toward precision therapies. Startups in the liquid biopsy sector, including Guardant Health and Grail, secured significant Series B funding, while emerging markets in Southeast Asia witnessed infrastructure expansions to bolster molecular testing capacity. These developments position the sector for a 12–15% CAGR through 2028, driven by AI integration and personalized medicine adoption.
